Breast cancer mortality in women is largely attributed to the metastasis of primary breast tumors. We have analysed the function of EphB6, a kinase-deficient receptor, in the invasive phenotype of breast cancer cell lines. We have demonstrated the loss of EphB6 protein in invasive breast carcinoma cell lines and absence of EphB6 transcript in a metastatic breast tumor specimen. The function of EphB6 in invasiveness was confirmed by the ability of EphB6 protein to decrease the in vitro invasiveness of MDA-MB-231, MDA-MB-435 and BT549 cells transfected with an EphB6 expression construct. In MDA-MB-231 cells, the decreased invasiveness appeared to be mediated by decreased transcript levels of matrix metalloproteinase (MMP)7 and MMP19, and increased transcript levels of tissue inhibitors of metalloproteinase 2. In addition to affecting invasiveness phenotype, EphB6 overexpression was also responsible for altering the growth rate and colony-forming efficiency of MCF-7 and MDA-MB-231 cells in a cell-line-specific manner. We suggest that the significant decrease in the invasiveness of MDA-MB-231 and other cell lines transfected with EphB6 is likely occurring by the ability of EphB6 to transduce signals to the nucleus and altering relevant gene expression.
Introduction
Breast cancer is the second leading cause of cancer deaths in women in the United States (Jemal et al., 2008) . These deaths are primarily attributed to the growth of secondary tumors following metastasis. Metastasis is a multistep process involving the invasion of the primary tumor cells into the adjacent tissues, intravasation, movement through the circulatory system, extravasation to a distant organ and finally, the growth of secondary tumors. The identification of genes involved in these steps is essential for developing better diagnostic and therapeutic modalities.
The availability of numerous breast carcinoma cell lines, with varying phenotypes (Soule et al., 1973; Cailleau et al., 1974; Thompson et al., 1992) , has allowed for the identification of genes involved in the progression of breast cancer (Nagaraja and Kandpal, 2004; Nagaraja et al., 2006; Kagara et al., 2007; Schagdarsurengin et al., 2007) . We have previously identified EphB6 as a molecule of interest in breast cancer by using representational difference analysis of MCF-7 and MDA-MB-231 cDNAs (Nagaraja et al., 2006) and semiquantitative RT-PCR (Fox and Kandpal, 2004) .
Eph receptors make up the largest family of receptor tyrosine kinases in humans with 14 members identified to date (Manning et al., 2002) . These proteins are divided into A and B groups based on their homology to one another as well as their affinity for their ligands. The ephrins are similarly divided into two classes based on their homology and binding affinities for their respective receptors (Nakamoto, 2000) . However, there are some documented cases of cross talk between receptor and ligand families (Himanen et al., 2004; Pasquale 2005) . The signaling events triggered by Eph-ephrin interactions are important during development and have more recently been implicated in cancer (Drescher, 1997; Xu and Wilkinson, 1997; Holmberg et al., 2000; Adams, 2002; Kullander and Klein, 2002; Surawska et al., 2004) . In particular, growing evidence suggests that Eph receptors are important in the invasiveness of various tumors (Campbell and Robbins, 2008) .
The loss of EphB6 has been correlated with a negative outcome in neuroblastoma, melanoma and non-smallcell lung carcinoma (Tang et al., 2000 (Tang et al., , 2001 (Tang et al., , 2004 Hafner et al., 2003; Mu¨ller-Tidow et al., 2005) . Our preliminary study demonstrated that the EphB6 transcript was not detectable in MDA-MB-231, an invasive breast carcinoma cell line (Fox and Kandpal, 2004) . The EphB6 cDNA was first cloned from normal human brain RNA and its protein product has since been shown to be involved in T-cell function (Matsuoka et al., 1997; Luo et al., 2001; Freywald et al., 2003) . EphB6, although kinase deficient, is a target for phosphorylation by EphB1 following stimulation with ephrinB1 or ephrinB2 (Munthe et al., 2000; Freywald et al., 2002; Matsuoka et al., 2005) .
Eph receptors regulate adhesive or repulsive signals and cell migration by mediating integrin activation and actin cytoskeletal rearrangements (Zou et al., 1999; Holmberg et al., 2000; Elowe et al., 2001; Miao et al., 2001; Kullander and Klein, 2002; Pratt and Kinch, 2003) . In certain cell lines, EphB6 can both positively and negatively regulate cell adhesion and migration depending on the concentration of the ephrinB2 ligand used for stimulation (Matsuoka et al., 2005) . The differential response to ephrin ligand concentration was correlated to Src kinase-dependent phosphorylation of the cytoplasmic domain of EphB6 (Matsuoka et al., 2005) . Another study has shown that EphB6 is constitutively associated with a functional phosphotyrosine-binding domain of the proto-oncogene c-Cbl (Freywald et al., 2002) . This observation suggests that the interaction between EphB6 and c-Cbl may require EphB6 tyrosine phosphorylation and confirms that EphB6 can in fact be phosphorylated and can participate in signaling.
Results
Absence of EphB6 correlates with a more aggressive phenotype in breast carcinoma cell lines We have previously shown that EphB6 mRNA is not detectable in the invasive breast carcinoma cell line MDA-MB-231 relative to MCF-7, a noninvasive breast carcinoma cell line, and MCF-10A, a 'normal' cell line generated by the transformation of normal breast epithelial cells (Fox and Kandpal, 2004; Nagaraja and Kandpal, 2004) . To better characterize the potential function of EphB6 in the progression of breast cancer, we have investigated the levels of EphB6 protein in various breast carcinoma cell lines. As shown in Figure 1 , EphB6 protein was undetectable in three out of the four cell lines that have previously been characterized as invasive (Madsen and Briand, 1990; Tong et al., 1999; Fox and Kandpal, 2004) . On the other hand, all noninvasive cell lines have significant amounts of EphB6 protein. In an attempt to glean the clinical relevance of EphB6 in breast cancer, a set of breast tumor specimens were evaluated for relative levels of EphB6 transcript. Three of these specimens represent noninvasive tumors whereas one specimen was isolated from a metastatic lesion. The results shown in Figure 2 indicate that the EphB6 transcript was not detected in the tumor specimen isolated from a metastatic site.
Levels of EphB6 in breast carcinoma cell lines impact their phenotypes
We altered the levels of EphB6 protein in MCF-7 and MDA-MB-231 cell lines by transfecting them with either a sense or an antisense expression construct of EphB6. OneStep RT-PCR amplifications were performed using 200 ng of RNA isolated from four tumors. EphB6 amplification was performed for 35 cycles and b-actin for 20 cycles. Reverse transcriptase (RT)-PCR products were separated on 1.5% agarose gels and photographed using Gel Doc (Bio-Rad) imaging software, quantified using SigmaGel gel analysis software (SPSS Science) and normalized to b-actin levels; error bars indicate standard deviation.
EphB6 and invasiveness of breast carcinoma cells BP Fox and RP Kandpal line, on the other hand, expressed no endogenous EphB6 and therefore only clones overexpressing EphB6 were generated. As shown in Figure 3 , the strategy chosen was sufficient to significantly alter the levels of EphB6 protein in these cells relative to the control clones. These clones now represent two distinct models by which we can assign a biological function for EphB6 in various experimental systems as described below.
The average doubling time of the MCF-7 clones overexpressing EphB6 (MCF-7 þ EphB6) was significantly less than the control clones, whereas the doubling time of MCF-7 þ B6 a.s. (antisense) clones (no detectable EphB6) was relatively higher (Table 1) . Interestingly, a comparison of growth rates in MDA-MB-231 clones overexpressing EphB6 showed no difference in growth rate relative to the control clones ( Table 2) .
The stably transfected cell lines were also used to determine what function EphB6 has in: (1) the colonyforming efficiency (CFE; a well-established parameter for tumorigenicity) of both cell lines, and (2) the motility and invasiveness of MDA-MD-231, phenotypes which are known to be regulated by other members of the Eph family of proteins (Campbell and Robbins, 2008) . Overexpression of EphB6 in MCF-7 led to a significant increase in the CFE as compared to the control MCF-7 clones, whereas silencing this gene has the opposite effect of significantly (Po0.001) reducing the CFE of these cells (Table 1 ). In addition, the size of a typical colony formed by EphB6-transfected MCF-7 cells was approximately three times larger in diameter than the biggest colony formed by native MCF-7 cells or the MCF-7 cells transfected with vector alone (Figure 4) .
Overexpression of EphB6 in MDA-MB-231 cells is capable of reducing the aggressive nature of these cells in vitro. As shown in Table 2 , overexpression of EphB6 in MDA-MB-231 cells reduced the CFE nearly eightfold (Po0.001). This is another example of a cell-line-specific effect of EphB6.
Cell migration and invasion assays were performed to determine the effect of EphB6 protein on the ability of MDA-MB-231 cells to migrate through uncoated or Matrigel-coated membranes, respectively. The motility of vector-transfected and EphB6-transfected cells, as determined by counting the number of cells migrating through the 8 mm pores of the uncoated membrane in 24 h, was comparable (Table 2 ). However, the movement of cells through the Matrigel-coated membrane depends on their ability to digest the artificial extracellular matrix (ECM) proteins and thus is a measure of invasiveness. A fourfold decrease (Po0.001) in the invasiveness of EphB6-transfected clones compared to the vector-transfected clones was observed (Table 2 ). It warrants mention that transient transfection of EphB6 into BT-549 and MDA-MB-435 cell lines, decreased their invasiveness by approximately 4-fold, which is consistent with the phenotype observed for EphB6-expressing clones of MDA-MB-231 cell line (data not shown).
The ability to degrade the ECM is an indicator of tumor cell invasiveness, and is partly regulated by matrix metalloproteinases (MMPs). The activity of MMP is regulated, at least in part, by tissue inhibitors of metalloproteinases (TIMPs). Transcript levels of MMP and TIMP could provide information relevant to the underlying biological mechanism responsible for the decrease in invasiveness of EphB6-expressing MDA-MB-231 cells. Representative pictures of semiquantitative RT-PCR products corresponding to MMP and TIMP transcripts are shown in Figure 5a along with quantitative analysis of these data (Figure 5b) . A significant decrease (Po0.001) in the amounts of MMP7 and MMP19 transcripts was observed in EphB6-expressing clones compared to vector-transfected clones. In addition, significantly higher levels (Po0.001) of TIMP2 were observed in EphB6-transfectants ( Figure 5 ). Interestingly, a significant decrease (Po0.001) in TIMP3 transcript was seen in the EphB6-expressing clones relative to the vector-transfected control cells. No differences in transcript expression were seen in MMP1, MMP11, MMP14, MMP16, MMP22, MMP24 and TIMP1. The remaining MMP and TIMP transcripts were not detectable in any of the clones under these conditions. The expression pattern of MMP7, MMP19 and TIMP2 in noninvasive cell lines MCF-7 and BT-20 was comparable to that observed for EphB6-expressing clones of MDA-MB-231 cell line (data not shown).
Discussion
EphB6 has previously been identified as an indicator of tumor phenotype in neuroblastoma, melanoma and non-small-cell lung carcinoma (Tang et al., 2000; Hafner et al., 2003; Mu¨ller-Tidow et al., 2005) . The analyses of EphB6 expression levels in breast carcinoma cell lines Figure 3 Analysis of EphB6 protein levels in MCF-7 and MDA-MB-231 clones. Total cell lysates (50 mg) were subjected to western blotting to determine EphB6 and b-actin protein levels in MCF-7 clones (a) and MDA-MB-231 clones (b) as described previously. These experiments were performed three times and the results obtained were consistent. a.s. ¼ antisense.
and a panel of breast tumor specimens presented here indicate that EphB6 may serve as a useful diagnostic marker in breast cancer. Specifically, EphB6 protein was not detectable in three out of four invasive breast carcinoma cell lines, but present in all noninvasive and one out of four invasive cell lines tested. Studies of the biological activity of EphB6 in cancers show that the CFE of the neuroblastoma cell line IMR5 decreased significantly following transfection with an expression construct of EphB6 (Tang et al., 2000) . Furthermore, overexpression of EphB6 in SY5Y neuroblastoma cells led to the formation of much smaller tumors in a mouse model of tumorigenicity as compared to native SY5Y cells (Tang et al., 2000) .
Metastasis is a multistep process involving but not limited to (1) the invasion of tumor cells into adjacent tissues, (2) entry into the circulation and (3) growth to produce a secondary tumor (Bashyam, 2002; Chambers et al., 2002; Fidler 2003) . It has been shown that several Eph receptors have significant functions in this process (Campbell and Robbins, 2008) . Ours is the first report demonstrating that EphB6 is capable of decreasing the in vitro invasiveness of MDA-MB-231, MDA-MB-435 and BT549 cells. Interestingly, overexpression of this protein in MCF-7 cells had the unexpected effect of increasing both the CFE and the size of colonies in the soft agar assay. Additionally, the doubling time of MCF-7 cells decreased following overexpression of EphB6. The increase in the size of colony can be partially attributed to the ability of transfected MCF-7 cells to divide significantly rapidly as compared to native MCF-7 cells. We have previously shown that the expression of EphB2, EphB3 and EphB4 differ in MCF-7 and MDA-MB-231 cells (Fox and Kandpal, 2004) and this can help explain the cell-line-specific effect on phenotypes. Furthermore, the transcript levels for ephrinB1 and ephrinB2 are significantly lower and ephrinB2 levels are relatively higher in MDA-MB-231 cells as compared to MCF-7 cells. To explain the differential effects of EphB6 on colony-forming efficiencies of MCF-7 and MDA-MB-231, it needs to be emphasized that EphB6 is known to mediate adhesion and migration in a concentration-dependent manner (Matsuoka et al., 2005) .
Eph receptors are known to heteromerize within their subclass (Himanen and Nikolov, 2003) . Although kinase deficient, it has been shown that EphB6 is phosphorylated upon dimerization with EphB1 (Freywald et al., 2002) . It is likely that EphB6 can be phosphorylated following dimerization with other EphB receptors as well. After it is phosphorylated, EphB6 can transduce signals in a phosphorylation-dependent manner (Luo et al., 2001; Freywald et al., 2002 Freywald et al., , 2003 . Taken together, these observations suggest that unique expression patterns of the other members of the EphB family could alter the nature and magnitude of signaling through EphB6.
MMPs (Hojilla et al., 2003; Malemud, 2006) and TIMPs can, in part, influence the invasiveness of MDA-MB-231 cells transfected with EphB6. In particular, decreased Values were determined by counting total number of colonies formed and dividing by the total number of cells added per well (1000), and multiplying it by 100 to yield a percentage. abundance of MMP7 and MMP19 transcripts and an increase in the levels of TIMP2 transcript are consistent with the observed decrease in invasiveness seen in the EphB6-overexpressing clones. Our results are supported by other reports indicating a correlation between EphA2 overexpression and MMP2 protein in pancreatic cells (Duxbury et al., 2004) and decreased MMP2 protein in ephrinB2-treated breast cancer cells (Noren et al., 2006) . EphrinB1, a ligand of EphB6, can mediate the secretion of MMP8 and the invasiveness of cancer cells . The differential effects of EphB6 overexpression on the levels of TIMP2 and TIMP3 may appear at odds with the decreased in vitro invasiveness of transfected MDA-MB-231 cells. However, the localization of TIMP2 and TIMP3 as well as some known phenotypic effects of varying levels of TIMP3 allow us to reconcile with the decreased levels of TIMP3 transcripts and reduced invasiveness of MDA-MB-231 cells. It is known that TIMP2 remains in the soluble form after it has been secreted whereas TIMP3 exists as tightly bound to ECM (Yu et al., 2000) . Interestingly, the loss of TIMP3 and its overexpression have both been linked to apoptosis (Fata et al., 2001; Bond et al., 2002; Ahonen et al., 2003; Mohammed et al., 2004) . In light of these reports, it is not unreasonable to believe that higher levels of TIMP2 and lower levels of TIMP3 transcripts are mediators of similar phenotypic effects in EphB6-transfected MDA-MB-231 cells. The mechanism of MMP and TIMP transcriptional regulation is not clear; however, it has been shown that Eph receptors (Lai et al., 2004) and ephrin ligands (Bong et al., 2007) can transduce signals to the nucleus through the Jak/STAT pathway. In addition, EphB6 is capable of suppressing signaling through the JNK pathway in T-cell development following stimulation with ephrinB1 (Freywald et al., 2003) . The changes observed in MMP7, MMP19 and TIMP2 transcript levels point to the potential involvement of EphB6 in regulating signaling events that culminate in the transcriptional regulation of these genes and in turn the invasiveness of these cells.
Materials and methods
Cell lines and growth media MCF-10A, a cell line established from normal breast epithelium, and seven breast carcinoma cell lines (MCF-7, BT-20, SkBr3, MDA-MB-231, MDA-MB-435, BT549 and Hs578T) were used in these investigations. All cell lines were cultured at 37 1C in the presence of 7% CO 2 . MCF-10A cells were grown in 1:1 Dulbecco's modified Eagle's medium (DMEM):F12 media (Gibco, Carlsbad, CA, USA) with 5% horse serum (Gibco), 20 mM HEPES (Gibco), 10 ng/ml EGF (Invitrogen, Carlsbad, CA, USA), 10 U/ml penicillin (Gibco), 10 mg/ml streptomycin (Gibco), 2.0 mM L-glutamine (Gibco), 10 mg/ml insulin (Invitrogen), 0.1 mg/ml cholera toxin (Sigma, St Louis, MO, USA) and 500 ng/ml hydrocortisone (Sigma), as described by Soule et al. (1973) . All other cell lines were grown in DMEM (Gibco) with 10% fetal bovine serum (FBS; Hyclone, Logan, UT, USA), 2.0 mM L-glutamine (Gibco), 1.0 mM sodium pyruvate (Gibco), 25 U/ml penicillin (Gibco) and 25 mg/ml streptomycin (Gibco) unless indicated otherwise (Thompson et al., 1992) .
RNA Isolation
Cell lysates were prepared by adding 1.0 ml of TRI reagent (Molecular Research Center Inc., Cincinnati, OH, USA) to an B90% confluent 10 cm 2 culture dish. The lysate was mixed with 200 ml of chloroform and centrifuged in a microfuge at 16 000 g for 15 min at 4 1C. RNA was precipitated from the aqueous phase by adding 250 ml of isopropanol and centrifuging at 16 000 g at 4 1C for 20 min. The pellet was then washed sequentially with 80 and 100% ethanol, resuspended in diethylpyrocarbonate-treated H 2 O and stored in aliquots at À80 1C. The amount of RNA present was determined by measuring their absorbance at 260 nm.
DNase treatment of total RNA RNA (20 mg) was treated with 500 ng DNaseI, 80 U RNasin (Promega, Madison, WI, USA) and 1.0 mM MgCl 2 in Tris buffer (40 mM Tris, pH 8) in a total volume of 50 ml. The reaction was carried out at 37 1C for 1 h and the DNase was inactivated by incubation at 65 1C for 30 min. The DNasetreated RNA was subjected to reverse transcriptase (RT)-PCR using primers spanning a small intron of the ephrinA4 gene. The absence of an amplified product indicated the elimination of genomic DNA in the RNA preparations.
Semiquantitative RT-PCR
The Qiagen OneStep RT-PCR kit was used for all reactions. Equal amounts of RNA, as confirmed by amplification of actin transcript, from each cell line were used in sets of parallel reactions. The protocol for RT-PCR has been described previously (Fox and Kandpal, 2004) . The primer sequences as well as the number of cycles used for each primer set are listed here. The forward actin primer, named actin F (5 0 -CTGACT GACTACCTC ATGAAG-3 0 ) corresponding to bases 626-646 of the NCBI database entry NM_001101, and the reverse actin primer, named actin R (5 0 -ATCCACATCTGCTGGAAG GTG-3 0 ) corresponding to bases 1143-1123 of the NCBI database entry NM_001101, were used for the normalization of RNA amounts.
The semiquantitative RT-PCR analysis of EphB6 transcript in the tumor RNA samples required a set of primers spanning an intron because DNase treatment was not performed. The EphB6 forward primer, named EphB6F2 (5 0 -AGAGCCAGAGGAG GATGGAG-3 0 ) corresponding to bases 1585-1604 of the NCBI database entry NM_004445, and the reverse primer, named EphB6R2 (5 0 -GGTCAGGGTGAAGGAGTGGGATTCGTC TTCTG-3 0 ) corresponding to bases 2404-2373 of NCBI database entry NM_004445, were used to amplify the EphB6 transcript from tumor RNAs. The expected product size from RNA is 820 bp and that from genomic DNA is 2.5 kb.
Transfection of cell lines with EphB6 constructs
Three EphB6 constructs (sense construct, antisense construct or empty vector) were individually transfected into MCF-7 and MDA-MB-231 cells. The EphB6-pCDNA3.1 þ construct (sense construct), containing the full-length EphB6 cDNA, was a generous gift from Dr Masaru Nakamoto (University of Aberdeen, Scotland, UK) and is described in Matsuoka et al. (2005) . The full-length EphB6 cDNA was cloned in the antisense orientation in pCDNA3.1 þ (antisense construct) following PCR amplification using EphB6-pCDNA3.1 þ as a template. MCF-7 cells were transfected with each of these constructs individually in separate plates using Lipofectamine 2000 (Invitrogen) according to the manufacturer's recommendations. The transfected cells were grown in media containing 500 mg/ml G418, and resistant clones were analysed for EphB6 transcript and protein levels. MDA-MB-231 cells were transfected with either the pCDNA3.1 þ (empty vector) or the EphB6-pCDNA3.1 þ construct and G418-resistant clones isolated.
Western blotting
The cells were grown to the logarithmic phase in appropriate media in 10 cm 2 plates as described. The medium was removed and the plates were washed with ice-cold phosphate-buffered saline. An aliquot (500 ml) of cell lysis buffer (Cell Signaling Technology, Inc., Danvers, MA, USA) containing 1 mM phenylmethylsulphonyl fluoride (Sigma) was added to each plate and the plates were kept on ice for 5 min. The lysates were sonicated four times for 5 s each using the Misonix 3000 sonicator at a setting of 2.0 and the homogenate centrifuged at 16 000 g in a microfuge at 4 1C for 10 min. An aliquot of supernatant (B50 mg of protein) was electrophoresed on a 10% SDS-polyacrylamide gel and the separated proteins were transferred from the gel to a polyvinylidene difluoride membrane (Amersham Biosciences, Piscataway, NJ, USA) and processed as described below for the detection of EphB6 or b-actin.
The membrane was blocked by incubating for 1 h at room temperature in a blocking buffer (Tris-buffered saline (TBS) containing 5% nonfat dry milk) and subsequently incubated with 5 mg of goat anti-mouse EphB6 polyclonal antibody (R&D systems, Inc., Minneapolis, MN, USA) in 15 ml of TBS containing 0.1% Tween 20 (TBS-T) and 5% bovine serum albumin at 4 1C overnight. This antibody was raised against the extracellular domain of the mouse EphB6. The blot was then washed three times for 5 min each with TBS-T at room temperature and then incubated with an horseradish peroxidase (HRP)-conjugated donkey anti-goat antibody (Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA) at a dilution of 1:100 000 in TBS-T for 1 h at room temperature. The membrane was washed three times for 5 min each with TBS-T and incubated with HRP substrate (Millipore, Billerica, MA, USA). The addition of the substrate generated a chemiluminescent signal that was detected following exposure to an Xray film, and the intensity of this signal was used to determine the relative abundance of the EphB6 protein.
To determine the relative amounts of total protein loaded for each sample, the membrane was washed to remove the bound antibodies as per the membrane manufacturer's recommendations. The membrane was reprobed with a monoclonal mouse antibody to human b-actin (Sigma) at a dilution of 1:3000. The presence of b-actin was detected by using HRP-conjugated, goat anti-mouse antibody (Santa Cruz Biotechnology) as described above.
Population doubling times
Cells in logarithmic phase of growth were collected, counted with a hemocytometer and seeded in individual wells of six-well plates with appropriate medium. The culture dishes were incubated at 37 1C in a 7% CO 2 incubator and cells were trypsinized from three wells every 24 h for a period of 7 days. The trypsinized cells were diluted in normal growth medium and counted using a hemocytometer. The doubling times were calculated by plotting cell numbers against time in a semilog plot.
Soft agar assay
The culture dishes were layered with 0.5% agar in 1 Â DMEM þ 10% FBS (with or without 500 mg/ml G418). A 6 ml suspension containing 4000 cells was made in a solution of 0.35% agar in 1 Â DMEM þ 10%FBS (with or without 500 mg/ml G418). Aliquots (1.5 ml) of the above cell suspension were placed in each of three wells of a six-well plate and incubated at 37 1C in a 7%CO 2 incubator for 18 days. The colonies were observed using an inverted microscope, counted and CFE expressed as a percentage of the initial cell count. Each experiment was performed three times to calculate mean ± s.d.
In vitro invasion and migration assays
The Matrigel invasion chamber (Becton Dickinson, Franklin Lakes, NJ, USA) was used as per the protocol recommended by the manufacturer. The invasion data were generated using membranes that have been coated with the synthetic ECM protein mixture (Matrigel), whereas the migration values were determined using uncoated inserts. The coated or uncoated membrane separates the two halves of the chamber. The upper chamber was filled with the cell suspension and a chemoattractant was placed in the lower chamber. Cells in the logarithmic phase of growth were trypsinized and diluted in serum-free media to a concentration of 30 000 cells per ml. A suspension of 15 000 cells (500 ml) was added to the upper side of three coated and three uncoated inserts. Conditioned media collected from MCF-7 cells growing in the logarithmic phase was used on the underside as a chemoattractant. The invasion chamber was placed in a 7% CO 2 incubator at 37 1C for exactly 24 h. The nonmigrating or noninvading cells that remained on top of the membrane were removed with a cotton swab and the cells on the underside were stained using the Hema 3 staining kit (Pierce, Rockford, IL, USA) and counted using a microscope. The relative migratory index was calculated by counting the number of cells in five high-powered ( Â 400) fields for each of the three uncoated inserts and these numbers were averaged. The invasiveness of the cells was determined by counting every invading cell and is expressed as a percentage of the initial cell count.
Statistical analysis
Statistical significance was determined by Student's t-test or by analysis of variation (ANOVA) using Sigma-Plot (Jandel Scientific) statistical software.
